A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
C Warren OlanowRobert A HauserDaniel J BurdickRohit DhallJoy Antonelle de MarcaidaRamon A GilDavid L KreitzmanLawrence W ElmerAndrew McGarryKarl Kieburtznull nullPublished in: Movement disorders : official journal of the Movement Disorder Society (2023)
P2B001 had superior efficacy to its individual components and was comparable with commercially used doses of pramipexole-ER with less worsening of sleepiness and fewer dopaminergic adverse events. These findings support considering once-daily P2B001 as initial therapy for patients with early PD. © 2023 International Parkinson and Movement Disorder Society.